Cargando…

The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins

Insulin-like growth factors elicit many responses through activation of phosphoinositide 3-OH kinase (PI3K). The tuberous sclerosis complex (TSC1-2) suppresses cell growth by negatively regulating a protein kinase, p70S6K (S6K1), which generally requires PI3K signals for its activation. Here, we sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Laura S., Findlay, Greg M., Gray, Alex, Tolkacheva, Tatiana, Wigfield, Simon, Rebholz, Heike, Barnett, Jill, Leslie, Nick R., Cheng, Susan, Shepherd, Peter R., Gout, Ivan, Downes, C. Peter, Lamb, Richard F.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2172316/
https://www.ncbi.nlm.nih.gov/pubmed/15249583
http://dx.doi.org/10.1083/jcb.200403069
_version_ 1782145042710790144
author Harrington, Laura S.
Findlay, Greg M.
Gray, Alex
Tolkacheva, Tatiana
Wigfield, Simon
Rebholz, Heike
Barnett, Jill
Leslie, Nick R.
Cheng, Susan
Shepherd, Peter R.
Gout, Ivan
Downes, C. Peter
Lamb, Richard F.
author_facet Harrington, Laura S.
Findlay, Greg M.
Gray, Alex
Tolkacheva, Tatiana
Wigfield, Simon
Rebholz, Heike
Barnett, Jill
Leslie, Nick R.
Cheng, Susan
Shepherd, Peter R.
Gout, Ivan
Downes, C. Peter
Lamb, Richard F.
author_sort Harrington, Laura S.
collection PubMed
description Insulin-like growth factors elicit many responses through activation of phosphoinositide 3-OH kinase (PI3K). The tuberous sclerosis complex (TSC1-2) suppresses cell growth by negatively regulating a protein kinase, p70S6K (S6K1), which generally requires PI3K signals for its activation. Here, we show that TSC1-2 is required for insulin signaling to PI3K. TSC1-2 maintains insulin signaling to PI3K by restraining the activity of S6K, which when activated inactivates insulin receptor substrate (IRS) function, via repression of IRS-1 gene expression and via direct phosphorylation of IRS-1. Our results argue that the low malignant potential of tumors arising from TSC1-2 dysfunction may be explained by the failure of TSC mutant cells to activate PI3K and its downstream effectors.
format Text
id pubmed-2172316
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21723162008-03-05 The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins Harrington, Laura S. Findlay, Greg M. Gray, Alex Tolkacheva, Tatiana Wigfield, Simon Rebholz, Heike Barnett, Jill Leslie, Nick R. Cheng, Susan Shepherd, Peter R. Gout, Ivan Downes, C. Peter Lamb, Richard F. J Cell Biol Research Articles Insulin-like growth factors elicit many responses through activation of phosphoinositide 3-OH kinase (PI3K). The tuberous sclerosis complex (TSC1-2) suppresses cell growth by negatively regulating a protein kinase, p70S6K (S6K1), which generally requires PI3K signals for its activation. Here, we show that TSC1-2 is required for insulin signaling to PI3K. TSC1-2 maintains insulin signaling to PI3K by restraining the activity of S6K, which when activated inactivates insulin receptor substrate (IRS) function, via repression of IRS-1 gene expression and via direct phosphorylation of IRS-1. Our results argue that the low malignant potential of tumors arising from TSC1-2 dysfunction may be explained by the failure of TSC mutant cells to activate PI3K and its downstream effectors. The Rockefeller University Press 2004-07-19 /pmc/articles/PMC2172316/ /pubmed/15249583 http://dx.doi.org/10.1083/jcb.200403069 Text en Copyright © 2004, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Research Articles
Harrington, Laura S.
Findlay, Greg M.
Gray, Alex
Tolkacheva, Tatiana
Wigfield, Simon
Rebholz, Heike
Barnett, Jill
Leslie, Nick R.
Cheng, Susan
Shepherd, Peter R.
Gout, Ivan
Downes, C. Peter
Lamb, Richard F.
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
title The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
title_full The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
title_fullStr The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
title_full_unstemmed The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
title_short The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
title_sort tsc1-2 tumor suppressor controls insulin–pi3k signaling via regulation of irs proteins
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2172316/
https://www.ncbi.nlm.nih.gov/pubmed/15249583
http://dx.doi.org/10.1083/jcb.200403069
work_keys_str_mv AT harringtonlauras thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT findlaygregm thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT grayalex thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT tolkachevatatiana thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT wigfieldsimon thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT rebholzheike thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT barnettjill thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT leslienickr thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT chengsusan thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT shepherdpeterr thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT goutivan thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT downescpeter thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT lambrichardf thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT harringtonlauras tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT findlaygregm tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT grayalex tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT tolkachevatatiana tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT wigfieldsimon tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT rebholzheike tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT barnettjill tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT leslienickr tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT chengsusan tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT shepherdpeterr tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT goutivan tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT downescpeter tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins
AT lambrichardf tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins